AstraZeneca Nexium Data Shows 47% Of Scripts Are First-Time PPI Users
Executive Summary
Nexium sales data from the U.K. and Germany shows that 47% of prescriptions are for patients new to proton pump inhibitors, AstraZeneca CEO Tom McKillop, PhD, reported at the company's year-end earnings conference in London Feb. 8.
You may also be interested in...
AstraZeneca Nexium Relying On Healing Rate, Symptom Maintenance
AstraZeneca's efforts to build a superiority claim for the proton pump inhibitor Nexium hinge on three elements of labeling.
AstraZeneca Nexium Relying On Healing Rate, Symptom Maintenance
AstraZeneca's efforts to build a superiority claim for the proton pump inhibitor Nexium hinge on three elements of labeling.
Wholesaler Forward-Buying Is Back, J&J Says; Rx Price Increases Pick Up
Johnson & Johnson is seeing an upward trend in forward-buying by wholesalers, CFO Robert Darretta told analysts Jan. 23 in New York City.